Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

NSAIDs and Statins Have No Impact on Renal Cell Carcinoma Risk

June 26th 2012

New data appears to undercut prior research by suggesting that neither NSAIDs nor statins influence the development of renal cell carcinoma.

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Urology Under Attack

June 21st 2012

As we head into the sweltering days of summer, physicians-and urologists in particular-face a series of challenges that can potentially impact the way we practice and how we manage our patients.

Dr. Escudier on Patients Preferring Pazopanib for mRCC

June 15th 2012

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Dr. Concepcion on Bladder Cancer Treatment and Costs

June 14th 2012

Dr. Raoul Concepcion, from the Urology Associates, PC, Nashville, TN, on Bladder Cancer Treatment and Costs.

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

June 2nd 2012

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Maximum 12-Month Follow-Up Suffices in More than Half of Men with Surgically-Treated Invasive Penile Cancer

May 16th 2012

In men with primary squamous cell carcinoma of the penis who have undergone surgery that removed all glanular epithelium a maximum 12-month follow-up period is recommended.

The Importance of Correct Coding in Specialty-Focused Cancer Treatment Centers

May 15th 2012

When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.

A Word of Welcome

May 14th 2012

It is with great pleasure that I welcome you to the inaugural issue of Urologists in Cancer Care.

Battling the Odds in RCC: Interview With Brian Rini, MD

May 5th 2012

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

Support for Dose Titration of Axitinib in AXIS Trial Results

April 5th 2012

The concept of dose titration in patients with mRCC who fail to achieve therapeutic levels on axitinib was validated by a secondary analysis.

FDA Approves Axitinib for Advanced Kidney Cancer Patients

January 27th 2012

The FDA approved axitinib for the treatment of patients with advanced RCC who have failed to respond to another drug.

Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell Carcinoma

January 18th 2012

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

Tivozanib Demonstrates Better PFS Than Sorafenib, but Failed to Meet Investors Expectations

January 3rd 2012

The investigational drug, tivozanib, showed improved rates of PFS in patients with advanced RCC than the already-approved sorafenib.

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

December 8th 2011

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

Tumoral CRP Levels Correlate With Survival in Renal Cell Carcinoma

November 30th 2011

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.

Dr. Rini Discusses the VEGF Targeted Agent Axitinib

November 17th 2011

Dr. Brian I. Rini from the Cleveland Clinic Discusses the VEGF Targeted Agent Axitinib